webinar register page

Webinar banner
Changing Landscape for PD-L1-high NSCLC Treatment

• Dr Ross Soo, National University Cancer Institute, Singapore
• Dr Mark Socinski, AdventHealth Medical Group Oncology & Hematology, USA
• Dr Roy Herbst , Yale Cancer Centre & Smilow Cancer Hospital, USA
• Dr Yuh-Min Chen, Taipei Veterans General Hospital, Taiwan


2000-2005 | Opening
2005-2020 | What are the treatments available for PD-L1-high population? (Dr Mark Socinski)
2020-2035 | What are some of the diagnostics in determining PD-L1-high status?
Is there any difference? (Dr Roy Herbst)
2035-2040 | Future Directions for PD-L1-high NSCLC treatments (Dr Ross Soo)
2040-2050 | Patient Case Study 1: PD-L1-high patient on Immuno-monotherapy (Dr Mark Socinski)
2050-2100 | Patient Case Study 2: PD-L1-high patient on Immuno-Chemo combination (Dr Yuh-Min Chen)
2100-2130 | Panel Discussion

Oct 22, 2020 08:00 PM in Kuala Lumpur

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Roche.